Current Surgical Therapy of Hepatic Colorectal Metastasis Aktuelle Chirurgie kolorektaler Lebermetastasen

IF 0.6 4区 医学 Q4 SURGERY European Surgery-Acta Chirurgica Austriaca Pub Date : 2008-12-03 DOI:10.1046/j.1563-2563.2002.02005.x
St. F. Stanziale, Y. Fong
{"title":"Current Surgical Therapy of Hepatic Colorectal Metastasis\n Aktuelle Chirurgie kolorektaler Lebermetastasen","authors":"St. F. Stanziale,&nbsp;Y. Fong","doi":"10.1046/j.1563-2563.2002.02005.x","DOIUrl":null,"url":null,"abstract":"<p><b>Summary:</b> <span>Background</span>: Liver resection represents the only cure for patients with hepatic metastases from colorectal cancers.<span>Methods</span>: The discussion will address which patients should be considered for hepatic resection, what are the appropriate diagnostic modalities to employ, and what are the hallmarks of surgical therapy. The biologic determinants of recurrence as the basis for rational patient selection for hepatectomy will be addressed. This review will then concentrate on recent data guiding adjuvant therapy, and emerging developments for staging.<span>Results</span>: Median survival of patients after liver resection for hepatic metastases is on the order of 40 months (45, 93, 105), five-year survival is 30 % – 40 %, and ten-year survival approximately 20 %. Operative mortality at most major centers is uniformly less than 5 %.<span>Conclusions</span>: These comparative results have made any random-assignment trial of resection versus nonresectional approach unethical and resection the standard of care.</p>","PeriodicalId":50475,"journal":{"name":"European Surgery-Acta Chirurgica Austriaca","volume":null,"pages":null},"PeriodicalIF":0.6000,"publicationDate":"2008-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1046/j.1563-2563.2002.02005.x","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Surgery-Acta Chirurgica Austriaca","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1046/j.1563-2563.2002.02005.x","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 2

Abstract

Summary: Background: Liver resection represents the only cure for patients with hepatic metastases from colorectal cancers.Methods: The discussion will address which patients should be considered for hepatic resection, what are the appropriate diagnostic modalities to employ, and what are the hallmarks of surgical therapy. The biologic determinants of recurrence as the basis for rational patient selection for hepatectomy will be addressed. This review will then concentrate on recent data guiding adjuvant therapy, and emerging developments for staging.Results: Median survival of patients after liver resection for hepatic metastases is on the order of 40 months (45, 93, 105), five-year survival is 30 % – 40 %, and ten-year survival approximately 20 %. Operative mortality at most major centers is uniformly less than 5 %.Conclusions: These comparative results have made any random-assignment trial of resection versus nonresectional approach unethical and resection the standard of care.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
目前肝结直肠癌转移的外科治疗
摘要:背景:肝切除是结直肠癌肝转移患者的唯一治疗方法。方法:讨论应考虑哪些患者进行肝切除术,采用哪些适当的诊断方式,以及手术治疗的特点。复发的生物学决定因素作为合理选择患者肝切除术的基础将被解决。这篇综述将集中于指导辅助治疗的最新数据,以及分期的新进展。结果:肝转移切除后患者的中位生存期为40个月(45、93、105),5年生存率为30% - 40%,10年生存率约为20%。大多数主要中心的手术死亡率一致低于5%。结论:这些比较结果使得任何切除与非切除方法的随机分配试验都是不道德的,切除是标准的治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.10
自引率
0.00%
发文量
36
审稿时长
6-12 weeks
期刊介绍: The journal European Surgery – Acta Chirurgica Austriaca focuses on general surgery, endocrine surgery, thoracic surgery, heart and vascular surgery. Special features include new surgical and endoscopic techniques such as minimally invasive surgery, robot surgery, and advances in surgery-related biotechnology and surgical oncology. The journal especially addresses benign and malignant esophageal diseases, i.e. achalasia, gastroesophageal reflux disease, Barrett’s esophagus, and esophageal adenocarcinoma. In keeping with modern healthcare requirements, the journal’s scope includes inter- and multidisciplinary disease management (diagnosis, therapy and surveillance).
期刊最新文献
Remote training and evaluation of a simulator-based training course for complex endovascular procedures. Training in vascular trauma surgery for non-vascular surgeons: Vascular trauma surgery skills course. Coping with a lack of evidence: living-donor kidney transplantation in the initial phase of the SARS-CoV-2 pandemic. 63rd Annual Meeting of the Austrian Society of Surgery. Delayed presentation of inflammatory breast carcinoma during the COVID-19 pandemic.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1